Centessa Pharmaceuticals (CNTA) Other Non-Current Assets (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Other Non-Current Assets data on file, last reported at $1.3 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $1.3 million, down 31.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 31.99% YoY), and the FY2025 annual result was $1.4 million, down 29.62% from the prior year.
• Other Non-Current Assets eased to $1.3 million in Q1 2026 per CNTA's latest filing, from $1.4 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $6.0 million in Q1 2023 and troughed at $619000.0 in Q1 2022.
• A 5-year average of $2.0 million and a median of $1.9 million in 2025 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets surged 875.77% in 2023, then sank 68.82% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $1.9 million in 2022, then surged by 35.85% to $2.6 million in 2023, then declined by 19.89% to $2.0 million in 2024, then fell by 29.62% to $1.4 million in 2025, then fell by 11.11% to $1.3 million in 2026.
• Business Quant data shows CNTA's Other Non-Current Assets at $1.3 million in Q1 2026, $1.4 million in Q4 2025, and $1.6 million in Q3 2025.